<DOC>
	<DOCNO>NCT00126438</DOCNO>
	<brief_summary>The study design study utility 123I-mIBG diagnostic imaging agent predict cardiac outcome subject heart failure comparison subject without cardiovascular disease .</brief_summary>
	<brief_title>Meta-Iodobenzylguanidine ( 123I-mIBG ) Scintigraphy Imaging Patients With Heart Failure Control Subjects Without Cardiovascular Disease</brief_title>
	<detailed_description>This phase 3 , open-label , multicenter trial investigate prognostic usefulness 123I-mIBG imaging identify subject New York Heart Association ( NYHA ) Class II III HF experience adverse cardiac event . The study consist maximum 587 subject ( 525 HF subject 62 control subject ) administer 123I-mIBG approximately 40 centre United States . Subject status monitor 6-week interval post-administration 123I-mIBG ass occurrence adverse cardiac event . The median follow-up expect 9 month .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Study subject must adults establish diagnosis heart failure ( New York Heart Association Class II III ) reduce left ventricular ejection fraction ( LVEF ) ( &lt; 35 % ) healthy volunteer without heart disease . Healthy volunteer eligible history diabetes mellitus , signs/symptoms neurological disease ( eg , Parkinson 's Disease , multiple system atrophy , Parkinsonian syndromes ) , diseases know affect sympathetic nervous system . Subjects New York Heart Association Class I IV heart failure eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>nuclear cardiology</keyword>
	<keyword>sympathetic innervation</keyword>
	<keyword>123I-mIBG</keyword>
</DOC>